What is Benchling?
Benchling operates at the intersection of biotechnology and enterprise software, providing a unified platform that digitizes the R&D lifecycle. Founded to address the technological limitations inherent in traditional academic research environments, the company offers a suite of tools that enable scientists to manage data, track experiments, and collaborate across global teams. Its market position is defined by its ability to support diverse sectors, including pharmaceutical development, agricultural innovation, and sustainable materials science. By replacing fragmented, legacy systems with a centralized, cloud-native architecture, Benchling empowers organizations to streamline their research processes and bring life-changing innovations to market with greater efficiency and precision.
How much funding has Benchling raised?
Benchling has raised a total of $418.9M across 9 funding rounds:
Angel/Seed
$900K
Unspecified
$5M
Private Equity
$7M
Series A
$7M
Series B
$14.5M
Series C
$34.5M
Series D
$50M
Series E
$200M
Series F
$100M
Angel/Seed (2014): $900K with participation from Y Combinator and Rock Health companies
Unspecified (2015): $5M led by Andreessen Horowitz and Thrive Capital
Private Equity (2016): $7M supported by Andreessen Horowitz and Thrive Capital
Series A (2016): $7M featuring Matt Huang, Geoff Ralston, Andreessen Horowitz, Thrive Capital, and Ashton Kutcher Network
Series B (2018): $14.5M backed by F-Prime Capital Partners, Benchmark Capital, and Thrive Capital
Series C (2019): $34.5M with participation from Y Combinator Continuity, Benchmark, Lead Edge Capital Management, Thrive Capital, and Menlo Ventures
Series D (2020): $50M led by Benchmark, ICONIQ Partners, Spark Capital, Lux Capital, Alkeon Capital Management LLC, and Thrive Capital
Series E (2021): $200M supported by Byerly Capital, Altimeter Capital, Spark Capital, Elad Gil, Thrive Capital, Alkeon Capital Management, Menlo Ventures, Lux Capital, Benchmark Holdings, Sequoia Capital Global Equities, Lead Edge Capital Management, and ICONIQ Capital
Series F (2021): $100M, investors not publicly disclosed
Key Investors in Benchling
Thrive Capital
Thrive Capital is an investment venture capital company that operates out of New York. Thrive Capital primarily deals in internet and software investments.
Benchmark
Benchmark is a prominent venture capital firm known for its early-stage investments in transformative technology companies and its hands-on approach to board-level guidance.
Andreessen Horowitz
Andreessen Horowitz is a premier venture capital firm that invests in bold entrepreneurs building the future through technology, with a strong focus on software and life sciences.
What's next for Benchling?
With the infusion of capital from its latest financing round, Benchling is well-positioned to scale its enterprise operations and deepen its product integration capabilities. The company is expected to focus on expanding its footprint within the global biotech ecosystem, potentially enhancing its data analytics and machine learning features to further automate complex research workflows. As the demand for digitized, high-throughput scientific research continues to accelerate, Benchling's strategic roadmap likely involves strengthening its competitive moat through increased R&D investment and the acquisition of talent to support its growing customer base of industry leaders and innovators.
See full Benchling company page
